


**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)


<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
11874-055-999	10/608,907
<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
Storer, et al.	2201

<b>FILING DATE</b>	<b>ART UNIT</b>
June 27, 2003	1623

**U.S. PATENT DOCUMENTS**

<b>*Examiner Initials</b>		<b>Document Number</b>	<b>Date mm/dd/yy</b>	<b>Name of Patentee or Applicant of Cited Document</b>	<b>Notes</b>
/TM/	A01	3,116,282	12/31/63	Hunter	
	A02	3,891,623	6/24/75	Vorbruggen, et al.	
	A03	3,480,613	11/25/69	Walton	
	A04	4,209,613	6/24/80	Vorbruggen	
	A05	4,294,766	10/13/81	Schmidt, et al.	
	A06	4,605,659	8/12/86	Verheyden, et al.	
	A07	4,689,404	8/25/87	Kawada, et al.	
	A08	4,754,026	6/28/88	Kawada, et al.	
	A09	5,034,394	7/23/91	Daluge	
	A10	5,122,517	6/16/92	Vince, et al.	
	A11	5,200,514	4/06/93	Chu	
	A12	5,322,955	6/21/94	Matsumoto, et al.	
	A13	5,372,808	12/13/94	Blatt, et al.	
	A14	5,391,769	2/21/95	Matsumoto, et al.	
	A15	5,676,942	10/14/97	Testa, et al.	
	A16	5,738,845	4/14/98	Imakawa	
	A17	5,744,600	4/28/98	Mansuri, et al.	
	A18	5,750,676	5/12/98	Vorbruggen, et al.	
	A19	5,830,455	11/3/98	Valtuena, et al.	
	A20	5,849,696	12/15/98	Chretien, et al.	
	A21	5,908,621	6/1/99	Glue, et al.	
	A22	5,928,636	7/27/99	Alber, et al.	
	A23	5,942,223	8/24/99	Bazer, et al.	
	A24	5,977,061	11/2/99	Holy, et al.	
	A25	5,977,325	11/2/99	McCarthy, et al.	
	A26	5,980,884	11/9/99	Blatt, et al.	
	A27	6,002,029	12/14/99	Hostetler, et al.	
	A28	6,063,628	5/16/00	Loeb, et al.	
▼	A29	6,140,310	10/31/00	Glazier	
/TM/	A30	6,153,594	11/28/00	Borretzen, et al.	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
-----------------	-------------------------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
11874-055-999	10/608,907
<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
Storer, et al.	2201

<b>FILING DATE</b>	<b>ART UNIT</b>
June 27, 2003	1623

**U.S. PATENT DOCUMENTS**

<b>*Examiner Initials</b>		<b>Document Number</b>	<b>Date mm/dd/yy</b>	<b>Name of Patentee or Applicant of Cited Document</b>	<b>Notes</b>
/TM/	A31	6,156,501	12/05/00	McGall, et al.	
	A32	6,248,878	6/19/01	Matulic-Adamic, et al.	
	A33	6,271,212	8/07/01	Chu, et al.	
	A34	6,340,690	1/22/02	Bachand, et al.	
	A35	6,369,040	4/09/02	Acevedo, et al.	
	A36	6,395,716	5/28/02	Gosselin, et al.	
	A37	6,444,652	9/3/02	Gosselin, et al.	
	A38	6,455,508	9/24/02	Ramasamy, et al.	
	A39	6,566,344	5/20/03	Gosselin, et al.	
	A40	6,566,365	5/20/03	Storer	
	A41	6,569,837	5/27/03	Gosselin, et al.	
	A42	6,605,614	8/12/03	Bachand, et al.	
	A43	6,748,161	6/8/04	Ko, et al.	
	A44	6,787,526	9/7/04	Bryant, et al.	
	A45	6,815,542	11/9/04	Hong, et al.	
	A46	6,812,219	11/2/04	LaColla, et al.	
	A47	6,831,069	12/14/04	Tam, et al.	
	A48	6,908,924	6/21/05	Watanabe, et al.	
	A49	6,927,291	8/9/05	Jin, et al.	
	A50	6,946,450	9/20/05	Gosselin, et al.	
	A51	6,965,033	11/15/05	Jiang, et al.	
	A52	7,056,895	6/6/06	Ramasamy, et al.	
	A53	7,094,770	8/22/06	Watanabe, et al.	
	A54	7,105,499	9/12/06	Carroll, et al.	
	A55	7,125,855	10/24/06	Bhat, et al.	
	A56	7,169,766	1/30/07	Sommadossi, et al.	
	A57	7,202,224	4/10/07	Eldrup, et al.	
	A58	2002/0147160	1/18/02	Bhat et al.	
↓	A59	2002/0019363	2/14/02	Ismaili, et al.	
/TM/	A60	2002/0035085	7/22/03	Sommadossi, et al.	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-055-999	10/608,907
	<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
	Storer, et al.	2201
	<b>FILING DATE</b>	<b>ART UNIT</b>
	June 27, 2003	1623

**U.S. PATENT DOCUMENTS**

<b>*Examiner Initials</b>		<b>Document Number</b>	<b>Date mm/dd/yy</b>	<b>Name of Patentee or Applicant of Cited Document</b>	<b>Notes</b>
/TM/	A61	2002/0052345	5/02/02	Erion, et al.	
	A62	2002/0099072	7/25/02	Bachand, et al.	
	A63	2002/0147160	10/10/02	Bhat, et al.	
	A64	2002/0173490	11/21/02	Jiang, et al.	
	A65	2003/0028013	2/06/03	Hong, et al.	
	A66	2003/0039630	2/27/03	Albrecht	
	A67	2003/0083306	5/01/03	Imbach, et al.	
	A68	2003/0083307	5/01/03	Devos, et al.	
	A69	2003/0124512	7/03/03	Styuver	
	A70	2003/0225028	12/04/03	Gosselin, et al.	
	A71	2003/0225037	12/04/03	Storer, et al.	
	A72	2003/0236216	12/25/03	Devos, et al.	
	A73	2004/0002596	1/01/04	Hong, et al.	
	A74	2004/0023921	2/05/04	Hong, et al.	
	A75	2004/0063622	4/01/04	Sommadossi, et al.	
	A76	2004/0097462	5/20/04	Sommadossi, et al.	
	A77	2004/0102414	5/27/04	Sommadossi, et al.	
	A78	2004/0110717	1/16/04	Bhat et al.	
	A79	2004/0121980	6/24/04	Martin, et al.	
	A80	2004/0229839	11/18/04	Babu, et al.	
	A81	2004/0248844	12/9/04	Ismaili, et al.	
	A82	2004/0259934	12/23/04	Olsen, et al.	
	A83	2004/0266996	12/30/04	Microbiologica Quimica E Farmaceutica Ltd., Brazil	
	A84	2005/0020825	1/27/05	Storer, et al.	
	A85	2005/0031588	2/10/05	Sommadossi, et al.	
	A86	2005/0038240	2/17/05	Connolly, et al.	
	A87	2005/0090463	4/28/05	Roberts, et al.	
↓	A88	2005/0101550	5/12/05	Roberts, et al.	
	A89	2005/0107312	5/19/05	Keicher, et al.	
/TM/	A90	2005/0113330	5/26/05	Imbach, et al.	

LAI-2881655v1

<b>EXAMINER</b> /Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b> 01/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
11874-055-999	10/608,907
<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
Storer, et al.	2201

<b>FILING DATE</b>	<b>ART UNIT</b>
June 27, 2003	1623

**U.S. PATENT DOCUMENTS**

<b>*Examiner Initials</b>		<b>Document Number</b>	<b>Date mm/dd/yy</b>	<b>Name of Patentee or Applicant of Cited Document</b>	<b>Notes</b>
/TM/	A91	2005/0137141	06/23/05	Hilfinger, et al.	
	A92	2005/0215511	09/29/05	Roberts, et al.	
	A93	2006/0040890	03/23/06	Martin; Joseph Armstrong, et al.	
	A94	2006/0111311	05/25/06	Keicher, et al.	
	A95	2006/0194835	08/31/06	Dugourd, et al.	
	A96	2006/0241064	10/26/06	Roberts, et al.	
	A97	2007/0015905	1/18/07	LaColla, et al.	
	A98	10/845,976	5/14/04	Storer, et al.	
	A99	11/005,443	12/06/04	Gosselin, et al.	
↓	A100	11/644,304	12/22/06	Mayes, et al.	
/TM/	A101	11/516,928	9/06/06	Sommadossi, et al.	

**FOREIGN PATENT DOCUMENTS**

<b>*Examiner Initials</b>		<b>Foreign Patent Document Country Code, Number, Kind Code (if known)</b>	<b>Date mm/dd/yy</b>	<b>Name of Patentee or Applicant of Cited Document</b>	<b>Notes</b>	<b>T</b>
/TM/	B01	CA 2252144	4/16/00	Miller, et al.		
	B02	DD 140254	2/20/80	Barwolff, et al.	English Abstract Provided	
	B03	DE 42 24 737	2/03/94	Schott	English Abstract Provided	
	B04	DE 102005012681	09/21/06	Weber, Lutz	English Abstract Provided	
	B05	EP 0 352 248	1/24/90	Medivir AB		
	B06	EP 0 526 655	2/10/93	Japan Tobacco Inc.		
	B07	EP 0 553 358	8/04/93	Japan Tobacco Inc.		
	B08	EP 0 587 364	3/16/94	Britton, et al.		
	B09	EP 0 742 287	11/13/96	McGall, et al.		
	B10	FR 1 581 628	9/19/69	Merck & Co. Inc.	English Abstract Provided	
	B11	FR 2,662,165	11/22/91	Univ. Pier et Curie	English Abstract Provided	
	B12	GB 1,542,442	3/21/79	Schering AG		
	B13	JP 2091022	3/30/90	Univ. of Minnesota	English Abstract Provided	
↓	B14	JP 61212592	9/20/86	Tokyo Tanabe Co. Ltd.	English Abstract Provided	
/TM/	B15	JP 61263995	11/21/86	Takeda Chemical Ind., Ltd.	English Abstract Provided	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-055-999	10/608,907
	<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
	Storer, et al.	2201
<b>FILING DATE</b>	<b>ART UNIT</b>	
	June 27, 2003	1623

### FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
/TM/	B16	JP 63215694	9/8/88	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B17	JP 06135988	5/17/94	Toagosei Chimical Ind., Ltd.	English Abstract Provided	
	B18	JP 06293645	10/21/94	Jpn. Kokai Tokkyo Koho	English Abstract Provided	
	B19	JP 09059292	3/04/97	Yamasa Shoyu Co. Ltd.	English Abstract Provided	
	B20	WO 94/01117	1/20/94	Koszalka, et al.		
	B21	WO 98/16184	4/23/98	ICN Pharmaceuticals		
	B22	WO 99/023104	5/14/99	Klecker, et al.		
	B23	WO 00/009531	2/24/00	Novirio Pharmaceuticals, Ltd.		
	B24	WO 00/025799	5/11/00	Gosselin, et al.		
	B25	WO 01/68663	9/20/01	Ribapharm Corp.		
	B26	WO 01/049700	07/12/01	Biochem Pharma Inc., Can.		
	B27	WO 01/091737	12/06/01	Sommadossi, et al.		
	B28	WO 02/03997	1/17/02	Ribapharm, Inc.		
	B29	WO 02/094289	5/15/02	F. Hoffmann-La Roche AG		
	B30	WO 02/100415	6/07/02	F. Hoffmann-La Roche AG		
	B31	WO 02/070533	9/12/02	Pharmasset, Ltd.		
	B32	WO 02/094289	11/28/02	F. Hoffmann-La Roche AG		
	B33	WO 02/100415	12/19/02	F. Hoffmann-La Roche AG		
	B34	WO 03/026589	4/3/03	Idenix Pharma.; CNRS; U. Montp.		
	B35	WO 03/026675	4/3/03	Idenix Pharma.; CNRS; U. Montp.		
	B36	WO 03/039523	5/15/03	Wengel		
	B37	WO 03/063771	8/7/03	Pharmasset, Ltd.		
	B38	WO 03/068162	8/21/03	Pharmasset, Ltd.		
	B39	WO 03/068164	8/21/03	Pharmasset, Ltd.		
	B40	WO 03/068244	8/21/03	Merck & Co., Isis Pharmaceuticals, Inc.		
	B41	WO 03/072757	2/28/03	Biota Inc.		
	B42	WO 03/081899	6/26/03	Ribapharm, Inc.		
▼	B43	WO 03/093290	11/13/03	Genelabs Technologies		
	B44	WO 03/099840	12/04/03	Eldrup, et al.		
/TM/	B45	WO 03/100017	12/04/03	Eldrup, et al.		

LAI-2881655v1

<b>EXAMINER</b> /Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b> 01/22/2008
<b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	I1874-055-999	10/608,907
	<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
	Storer, et al.	2201
	<b>FILING DATE</b>	<b>ART UNIT</b>
	June 27, 2003	1623

### FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
/TM/	B46	WO 04/002422	1/8/04	Idenix Ltd.; Univ. D.S. Cagliari		
	B47	WO 04/002999	1/8/04	Idenix Ltd.; Univ. D.S. Cagliari		
	B48	WO 04/003000	1/8/04	Idenix Ltd.; Univ. D.S. Cagliari		
	B49	WO 04/028481	4/08/04	Genelabs Technologies, Inc.		
	B50	WO 04/041203	5/21/04	Xenopore, Inc., USA		
	B51	WO 04/043977	5/27/04	Prakush, et al.		
	B52	WO 04/043978	5/27/04	Baker, et al.		
	B53	WO 04/044132	5/27/04	Baker, et al.		
	B54	WO 04/046159	6/03/04	F. Hoffmann-La Roche AG		
	B55	WO 04/046331	6/03/04	Idenix Cayman		
	B56	WO 04/052899	6/24/04	Idenix Cayman Limited		
	B57	WO 04/058792	7/15/04	Idenix Cayman Limited		
	B58	WO 04/072090	8/26/04	Merck & Co., Inc.		
	B59	WO 04/084796	10/07/04	Pharmasset, Ltd.		
	B60	WO 04/096149	11/11/04	Idenix Cayman Limited		
	B61	WO 04/106356	12/9/04	Syddansk Universitet		
	B62	WO 05/003147	01/13/05	Pharmasset, Ltd.		
	B63	WO 05/020884	03/10/05	CENT NAT RECH SCI.		
	B64	WO 05/020885	03/10/05	Isis Pharmaceuticals, Inc., USA		
	B65	WO 05/042556	05/12/05	Genelabs Technologies, Inc., USA		
	B66	WO 06/016930	02/16/06	Intermune, Inc.		
	B67	WO 06/037028	04/06/06	CENT NAT RECH SCI		
	B68	WO 06/037227	04/13/06	Migenix Inc., Can.		
	B69	WO 06/063717	6/22/06	Febit Biotech GMBH		
	B70	WO 06/065335	06/22/06	Merck & Co. Inc., USA		
	B71	WO 06/097323	09/21/06	Weber, Lutz		
	B72	WO 06/100087	09/28/06	Novartis A.G.		
	B73	WO 06/121820	11/16/06	Valeant Research & Development		
▼	B74	WO 06/130532	12/07/06	Novartis AG, Switz.		
/TM/	B75	WO 07/011777	01/25/07	Novartis A.-G., Switz.		

LAI-2881655v1

<b>EXAMINER</b> /Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b> 01/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
11874-055-999	10/608,907
<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
Storer, et al.	2201

<b>FILING DATE</b>	<b>ART UNIT</b>
June 27, 2003	1623

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Notes	T
/TM/	B76	WO 07/025304	01/03/07	University of Oxford; Idenix Pharmaceuticals; et al.		

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/TM/	C01	Alt, et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Ptent and Specific Inhibitors of Hepatitis C Viral Translation." Arch. Virol. (1997) 142: 589-599.	
	C02	Alt, et al., "Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides." Hepatology, 22:707-717 (1995).	
	C03	Altmann, et al., "The Synthesis of 1'-Methyl Carbocyclic Thymidine and Its Effect on Nucleic Acid Duplex Stability," Syntett, Thieme Verlag, Stuttgart, De, 10:853-855 (1994).	
	C04	Beigelman, et al., "Epimerization During the Acetylation of 3-O-Acetyl-5-O-Benzoyl-1,2-o-Isopropylidene-3-C-Methyl-a, D-Ribofuranose. Synthesis of 3'-C-Methylnucleosides with the B-D-ribo-and a-D-arabino Configurations," Carbohydrate Research, 181:77-88 (1988).	
	C05	Beigelman, et al., "Functionally complete analogs of nucleosides. The use of D-gluclose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides. Biorrganicheskaya Khimiya. 1986, Vol. 12(10), pp. 1359-65.	
	C06	Bhopale, Girish Mahadeorao, et al., "Emerging drugs for chronic hepatitis C," Hepatology Research (2005), 32(3), 146-153.	
	C07	Billlich, et al., "Nucleoside Phosphotransferase from Malt Sprouts." Biol. Chem. Hoppe-Seyler, Vol. 367, pp. 267-278, April 1986.	
	C08	Bio, et al., "Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor." Journal of Organic Chemistry (2004), 69(19), 6257-6266.	
	C09	Bloch, A., et al., "The Role of the 5'-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase," J. Med. Chem., 10(5):908-12 (September 1967).	
	C10	Brown & McFarlin, et al., J. Am. Chem. Soc. 1958, 80, 5372-76.	
	C11	Bryant, M.L., et al., "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," Antimicrobial Agents and Chemotherapy, 45(1):229-235 (January 2001).	
	C12	Cappellacci, et al. "Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists." Journal of Medicinal Chemistry (2005), 48(5), 1550-1562.	
	C13	Carroll, S.S., et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs," J. Biol. Chem., 278(14): 11979-11984 (2003).	
	C14	Carroll, S.S., "Nucleoside analog inhibitors of hepatitis C virus replication," Infectious Disorders: Drug Targets (2006), 6(1), 17-29.	
	C15	Cavelier, F., et al., "Studies of Selective Boc Removal in the Presence of Silyl Ethers," Tetrahedron Letters, 37: 5131-5134 (1996).	
	C16	Chand, Pooran; et al., "Synthesis of (2S,3S,4R,5R)-2-(4- amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." Collection Symposium Series (2005), 7(Chemistry of Nucleic Acid Components), 329-332.	
↓	C17	Chiaramonte, et al., "Inhibition of CMP-Sialic Acid Transport into Golgi Vesicles by Nucleoside Monophates." Biochemistry 2001, 40, 14260-14267.	
/TM/	C18	Clark, et al., "Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication." Journal of Medicinal Chemistry (2005), 48(17), 5504-5508.	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-055-999	10/608,907
	<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
	Storer, et al.	2201
<b>FILING DATE</b>	<b>ART UNIT</b>	
	June 27, 2003	1623

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/TM/	C19	Coelmont, Lotte, "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methycytidine, the active component of valopicitabine," <i>Antimicrobial Agents and Chemotherapy</i> (2006), 50(10), 3444-3446.	
	C20	Cook, G.S., "Improving the treatment of hepatitis C infection in the UK," <i>Expert Opinion on Pharmacotherapy</i> , (2007) Vol. 8, No. 2, pp. 183-191.	
	C21	Cornberg, M., et al., "Present and future therapy for hepatitis C virus," <i>Expert review of Anti-Infective Therapy</i> , (2006) Vol. 4, No. 5, pp. 781-793.	
	C22	Cretton-Scott, E., et al., "Pharmacokinetics of B-L-2'-Deoxyctidine Prodrugs in Monkeys," <i>Antiviral res.</i> , 50:A44 (2001).	
	C23	Czernicki, S., et al., "Synthesis of various 3'-branched 2', 3'-unsaturated pyrimidine nucleosides as potential anti-HIV agents," <i>J. Org. Chem.</i> , 57: 7325-7328 (1992).	
	C24	Dalpiaz, et al., "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." <i>European Journal of Pharmacology</i> (2002), 448(2-3), 123-131	
	C25	Davis, G.L., "New Therapies: Oral Inhibitors and Immune Modulators," <i>Clinics in Liver Disease</i> , (2006) Vol. 10, No. 4, pp. 867-880.	
	C26	Davisson, V.J., et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," <i>J. Org. Chem.</i> , 52(9):1794-1801 (1987).	
	C27	Ding, et al., "Synthesis of 2'- $\beta$ -C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2005), 15(3), 725-727.	
	C28	Ding, et al., "Synthesis of 9-(2'- $\beta$ -C-methyl- $\beta$ -D-ribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication." <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2005), 15(3), 709-713	
	C29	Dutartre, H., et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," <i>Antimicrobial Agents and Chemotherapy</i> , (2006) Vol. 50, No. 12, pp. 4161-4169.	
	C30	Eldrup, et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication." <i>Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry</i> (2004), 47(21), 5284-5297.	
	C31	Eldrup, et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase.", <i>Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry</i> (2004), 47(9), 2283-2295.	
	C32	Faivre-Buet, et al., "Synthesis of J'-Deoxypsicofuansyl-Dexoynucleosides as Potential Anti-HIV Agents." <i>Nucleosides &amp; Nucleotides</i> , vol. 11, no. 7, 1992, pages 1411-1424.	
	C33	Feast, A.A.J., et al., "Studies on the D-Glucosaccharinic Acids," <i>Acta Chemica Scandinavica</i> 19(5):1127-1134 (1965).	
	C34	Fox, J. J., et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," <i>J. Am. Chem. Soc.</i> , 81: 178-187 (January 5, 1959).	
	C35	Franchetti, et al., "Antitumor Activity of C-Methyl- $\beta$ -D-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors." <i>Journal of Medicinal Chemistry</i> (2005), 48(15), 4983-4989.	
	C36	Fujimori, et al., "A Convenient and Stereoselective Synthesis of 2'-Deoxy-[beta]-L-nucleosides," <i>Nucleosides &amp; Nucleotides</i> , 11(2-4), 341-349 (1992); only CAPLUS abstract supplied.	
	C37	Furukawa, Y., et al. "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," <i>Chem. Pharm. Bull.</i> , 16(6):1076-1080 (June 1968).	
	C38	Galderisi, U., et al., "Antisense oligonucleotides as therapeutic agents," <i>Journal of Cellular Physiology</i> , 181(2):251-257 (November 1999).	
▼	C39	Gallo, et al., "2'-C-Methyluridine Phosphoramidite: A New Building Block for the Preparation of RNA Analogues Carrying the 2'-hydroxyl Group." <i>Tetrahedron</i> , 57 (2001), 5707-5713.	
/TM/	C40	Girardet, et al., "Synthesis and Cytotoxicity of 4-Amino-5-oxopyrido[2,3-d]pyrimidine Nucleosides." <i>Journal of Medicinal Chemistry</i> (2000), 43(20), 3704-3713.	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
11874-055-999	10/608,907
<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
Storer, et al.	2201

<b>FILING DATE</b>	<b>ART UNIT</b>
June 27, 2003	1623

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/TM/	C41	Gretch, D.R., "Use and interpretation of HCV diagnostic tests in the clinical setting." <i>Clinics in Live Disease</i> , November 1997, Vol. 1, No. 3, pp. 547-557.	
	C42	Grouiller, et al., "Novel-p-toluenesulfonylation and Thionocarbonylation of Unprotected Thymine Nucleosides," <i>Synlett</i> . 1993: 221-222 (1993).	
	C43	Grouiller, et al., "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent." <i>J. Pharm. Belg.</i> , 47(4), 381-3 (1992).	
	C44	Haraguchi, et al., "Preparation and Reactions of 2'-and 3'- Vinyl Bromides of Uracil Nucleosides: Versatile Synthons for Anti-HIV Agents," <i>Tetrahedron Letters</i> , 32(28): 3391-94 (1991).	
	C45	Haraguchi, et al., "Stereoselective Synthesis of 1'-C-Branched Uracil Nucleosides from Uridine," <i>Nucleotides &amp; Nucleosides</i> , 14(3-5): 417-420 (1995).	
	C46	Harry-O'Kuru, et al., "2'-C-Alkylribonucleosides: Design, Synthesis and Conformation," <i>Nucleosides &amp; Nucleotides</i> , vol. 16: 1457-60 (1997).	
	C47	Hattori, H., et al., "Nucleosides and nucleotides 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine and -uracil," <i>J. Med. Chem.</i> , 41: 2892-2902 (1998).	
	C48	Hayakawa, et al., "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2'- and 3'-positions." <i>Chemical &amp; Pharmaceutical Bulletin</i> (1987), 35(6), 2605-8.	
	C49	Hoard, D.E., et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," <i>J. Am Chem. Soc.</i> , 87(8):1785-1788 (April 20, 1965).	
	C50	Holy, A., "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides fo the Pyrimidine Series," <i>Collect. Czech. Chem. Commun.</i> , 37(12): 4072-4087 (1972).	
	C51	Iglesias, et al., "Complete and Regioselective Deacetylation of Peracetylated Uridines Using a Lipase." <i>Biotechnology Letters</i> 22: 361-365, 2000.	
	C52	Imori, et al., "2'-C-, 3'-C-, and 5'-C-Methylsangivamycins: conformational lock with the methyl group." <i>Tetrahedron Letters</i> (1991), 32(49), 7273-6.	
	C53	Imori, et al., "A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases." <i>Nucleic Acids Symposium Series</i> (1992), 27(Nineteenth Symposium on Nucleic Acids Chemistry, 1992), 169-70.	
	C54	Iino, T., et al., "Nucleosides and nucleotides 139. Stereoselective synthesis of (2'S)-2'-C-alkyl-2'-deoxyuridines," <i>Nucleosides &amp; Nucleotides</i> , 15(1-3): 169-181 (1996).	
	C55	Ikegashira, K., et al., "Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors," <i>Journal of Medicinal Chemistry</i> , (30 Nov 2006) Vol. 49, No. 24, pp. 6950-6953.	
	C56	Imai, K., et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." <i>J. Org. Chem.</i> , 34(6): 1547-1550 (June 1969).	
	C57	Itoh, et al., "Divergent and Stereocontrolled Approach to the Synthesis of Uracil Nucleosides Branched at the Anomeric Position," <i>J Org Chem</i> , 60(3): 656-662 (1995).	
	C58	Kakefuda, et al., "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: synthesis of 2',3'-dideoxy-2'-C-methyl- and -2'-C-ethynyl-β-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." <i>Tetrahedron</i> (1993), 49(38), 8513-28	
↓	C59	Kamaike, K., et al., "An efficient method for the synthesis of [4-15N]cytidine, 2'-deoxy[4-15N]cytidine, [6-15N]adenosine, and 2'-deoxy[6-15N]adenosine derivatives," <i>Nucleosides and Nucleotides</i> , 15(1-3): 749-769 (1996).	
/TM/	C60	Kaneko, M., et al., "A convenient synthesis of cytosine nucleosides," <i>Chem. Pharm. Bull.</i> , 20:1050-1053 (1972).	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
11874-055-999	10/608,907
<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
Storer, et al.	2201

<b>FILING DATE</b>	<b>ART UNIT</b>
June 27, 2003	1623

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/TM/	C61	Kawana, et al., "The Deoxygenation of Tosylated Adenosine Derivatives with Grignard Reagents," <i>Nucleic Acids Symp Ser</i> , 17:37-40 (1986).	
	C62	Kempe, T., et al., "Selective 2'-Benzoylation at the Cis 2', 3'-diols of Protected Ribonucleosides. New Solid Phase Synthesis of RNA and DNA-RNA Mixtures," <i>Nucleic Acids Res.</i> , 10(21):6695-6714 (November 11, 1982).	
	C63	Kerr, S.G., et al., "N-(Dialkylamino)Methylene Derivatives of 2'-Deoxycytidine and Arabinocytidine: Physicochemical Studies for Potential Prodrug Applications," <i>J. Pharm. Sci.</i> , 83(4): 582-586 (April 1994).	
	C64	Kim, et al., "A Novel Nucleoside Prodrug-Activating Enzyme: Substrate Specificity of Biphenyl Hydrolase-like Protein," <i>Molecular Pharmaceutics</i> (2004), 1(2), 117-127.	
	C65	Klumpp, et al., "The Novel Nucleoside Analog R1479 (4'-Azidocytidine) is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture." <i>The Journal of Biological Chemistry</i> , Vol. 281, No. 7, pp. 3793-3799, February 17, 2006.	
	C66	Lai, V.C.H., et al., "Mutational analysis of bovine viral diarrhea virus RNA-dependant RNA polymerase," <i>J. Virol.</i> , 73(12):10129-101136 (December 1999).	
	C67	Landowski, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," <i>Journal of Pharmacology and Experimental Therapeutics</i> (2006), 316(2), 572-580.	
	C68	Lavaire, S., et al., "3'-deoxy-3'-C-trifluoromethyl nucleosides: Synthesis and antiviral evaluation," <i>Nucleosides &amp; Nucleotides</i> , 17(12): 2267-2280 (1998).	
	C69	Le Pogam, et al., "In Vitro Selected Con1 Subgenomic Replicons Resistant to 2'-C-Methyl-Cytidine or to R1479 Show Lack of Cross Resistance." <i>Virology</i> 351 (2006), 349-359.	
	C70	Le Pogam, et al., "Selection and Characterization of Replicon Variants Dually Resistant to Thymidine- and Palmitate-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus." <i>Journal of Virology</i> , Vol. 80, No. 12, June 2006, p. 6146-6154.	
	C71	Leysen, P., et al., "Perspectives for the treatment of infections with Flaviviridae," <i>Clinical Microbiology Reviews</i> (Washington D.C.) 13(1): 67-82 (January 2000).	
	C72	Lin, T.S., et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," <i>Tetrahedron Letters</i> , 51(4): 1055-1068 (1995).	
	C73	Lopez Aparicio, F.J., et al., "Synthesis of Saccaric Acid Derivatives," <i>Carbohydrate Res.</i> , 129:99 (1984).	
	C74	Lopez-Herrera, F.J., et al., "A New Synthesis of 2-C Methyl-D-Ribono-1, 4-Lactone and the C-(/C-13 Fragment of Methynolide," <i>J. Carbohydrate Chemistry</i> , 13(5): 767-775 (1994).	
	C75	Magia, Giovanni, et al., "Lack of stereospecificity of suid pseudorabies virus thymidine kinase," <i>Biochem. J.</i> , 294(2): 381-385 (1993).	
	C76	Mansour, T.S., et al., "Editorial," <i>Anti-Infective Agents in Medicinal Chemistry</i> , (2007) Vol. 6, No. 1, pp. 1.	
	C77	Markland W., et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," <i>Antimicrobial Agents and Chemotherapy</i> , April 2000, Vol. 44, No. 4, pp. 859-866.	
	C78	Martin, J., et al., "Synthesis and Antiviral Activity of Monofluoro and Difluoro Analogues of Pyrimidine Deoxyribonucleosides Against Human Immunodeficiency Virus (HIV-1). <i>J. Med. Chem.</i> 1990, 33, 2137-2145.	
	C79	Martin, X., et al., "Intramolecular hydrogen bonding in primary hydroxyl of thymine 1-(1-deoxy-β-D-pisofuranosyl)nucleoside," <i>Tetrahedron</i> , 50(22): 6689-6694 (1994).	
↓	C80	Matsuda, et al., "Alkyl Addition Reaction of Pyrimidine 2'-Ketoanucleosides: Synthesis of 2'-Branched-Chain Sugar Pyrimidine Nucleosides (Nucleosides and Nucleotides. LXXXI)" <i>Chem Pharm Bull</i> , Vol. 36(3):945-53 (1988).	
/TM/	C81	Matsuda, et al., "Nucleosides and Nucleotides 104. Radical and Palladium-Catalyzed Deoxygenation of the Allylic Alcohol Systems in the Sugar Moiety of Pyrimidine Nucleosides." <i>Nucleosides &amp; Nucleotides</i> , Dekker, New York, NY, U.S., vol. 11, no. 2/4, 1992, pages 197-226.	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
11874-055-999	10/608,907
<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
Storer, et al.	2201

<b>FILING DATE</b>	<b>ART UNIT</b>
June 27, 2003	1623

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/TM/	C82	The Merck Index, 12th edition, 1996, Page 275	
	C83	Mikhailov, S.N., et al., "Synthesis and properties of 3' -C-methylnucleosides and their phosphoric esters," Carbohydrate Research, vol. 124, 1983, pp. 75-96.	
	C84	Mikhailov, S.N., et al., "Hydrolysis of 2'- and 3'-C-methyluridine 2'-, 3'-monophosphates and Interconversion and dephosphorylation of the resulting 2'- and 3'-monophosphates: Comparison with the reactions of Uridine monophosphates," <i>J. Org. Chem.</i> , Vol. 57: 4122-26 (1992).	
	C85	Mikhailov, S.N., et al., "Substrate properties of C'-methylnucleoside and C'-methyl-2'-deoxynucleoside 5'-triphosphates in RNA and DNA synthesis reactions catalysed by RNA and DNA polymerases," <i>Nucleosides &amp; Nucleotides</i> , 10(1-3): 339-343 (1991).	
	C86	Miles, et al., "Circular Dichroism of Nucleoside Derivatives. IX. Vicinal Effects on the Circular Dichroism of Pyrimidine Nucleosides." <i>Journal of the American Chemical Society</i> . 92:13, July 1, 1970.	
	C87	Moiseyev, et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases." <i>FEBS Letters</i> (1997), 404(2,3), 169-172	
	C88	Moore, et al., "Synthesis of Nucleotide Analogues That Potently and Selectively Inhibit Human DNA Primase." <i>Biochemistry</i> (2002), 41(47), 14066-14075.	
	C89	Nishiguchi, S., et al., "Methods to Detect Substitutions in the Interferon-Sensitivity-Determining Region of Hepatitis C virus 1b for Prediction of Response to Interferon Therapy," <i>Hepatology</i> . January 2001, Vol. 33, No. 1, pp. 241-247.	
	C90	Nishimura, T. et al. "Studies on Synthetic Nucleosides. Trimethylsilyl Derivatives of Pyrimidine and Purines," <i>Chemical &amp; Pharmaceutical Bulletin</i> (1964), vol. 12, pp. 352-356.	
	C91	Novak, J.J.K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C-Methyl-Erythro-D-Pentono-1, 4-Lactones," <i>Collection Czechoslov. Chem. Commun.</i> , 39:869-882 (1974).	
	C92	Novak, J.J.K. & Sorm, F., "Nucleic Acid Components and Their Analogues. CXX. 2-C-Methyl-D-Ribose and Its Derivatives," <i>Collection Czechoslov. Chem. Commun.</i> , 34:857-866 (1969).	
	C93	Oivanen, M., et al., "Additional evidence for the exceptional mechanism of the acid-catalyzed hydrolysis of 4-oxopyrimidine nucleosides: Hydrolysis of 1-(1-alkoxyalkyl)uracils, seconucleosides, 3'-C-alkyl nucleosides and nucleoside 3', 5'-cyclic monophosphates," <i>J. Chem. Soc. Perkin Trans. 2</i> , 1994: 309-314 (1994).	
	C94	Pagliaro, L., et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. EPATOLOGIA: IERI, OGGI E (FORSE) DOMANI," <i>Recenti Progressi in Medicina</i> , (2006) Vol. 97, No. 12, pp. 741-750.	
	C95	Pierra, C., et al., "Comparative Studies of Selected Potential Prodrugs of B-L-dC, A Potent and Selective Anti-HBV Agent," <i>Antiviral Res.</i> , 50:A79 (2001), Abstract no. 138.	
	C96	Pierra, C., et al., "NM 283, and efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine," <i>Nucleosides, Nucleotides and Nucleic Acids</i> (2005), 24(5-7), 767-770.	
	C97	Pierra, C., et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), and Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine," <i>Journal of Medicinal Chemistry</i> (2006), 49(22), 6614-6620.	
	C98	Reist, et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars." <i>Journal of Organic Chemistry</i> (1962), 27 3279-83.	
	C99	Robins, et al., "Purine Nucleosides. XXIX. The Synthesis of 2'-Deoxy-L-adenosine and 2'-Deoxy-L-guanosine and Their [alpha] Anomers," <i>Journal of Organic Chemistry</i> , 35(3), 636-639 (March 1970).	
	C100	Rong, et al., "The Synthesis and Conformation of 2'- and 3'-Hypermodified Tricyclic Nucleosides and Their Use in the Synthesis of Novel 2'- or 3'-Isomeric 4(7)-Substituted Isoxazolidine-nucleosides," <i>Tetrahedron</i> Vol. 50, No. 16, pp. 4921-4936. (1994).	
↓	C101	Roque-Afonso, AM, et al., "Performance of TRUGENE hepatitis C virus 5' noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination," <i>Journal of Viral Hepatitis</i> . September 2002, Vol. 9, Issue 5, pp. 385-389.	
/TM/	C102	Sakthivel, et al., "Direct SNAr amination of fluorinated imidazo[4,5- c]pyridine nucleosides: efficient syntheses of 3-fluoro-3deazaadenosine analogs." <i>Tetrahedron Letters</i> (2005), 46(22), 3883-3887..	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11874-055-999	10/608,907
APPLICANT	CONFIRMATION NO.
Storer, et al.	2201
FILING DATE	ART UNIT
June 27, 2003	1623

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/TM/	C103	Sakthivel, et al. "Electrophilic fluorination of 5- (cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3- deazaguanosine analogues." <i>Synlett</i> (2005), (10), 1586-1590.	
	C104	Saladino, R., et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," <i>J. chem. Soc., Perkin Trans. I</i> , 21: 3053-3054 (1994).	
	C105	Samano, et al., "Nucleic Acid Related Compounds. 77. 2',3'-Didehydro-2', 3'-Dideoxy-2' (and 3')-Methylnucleosides Via [3,3]-Sigmatropic Rearrangements of 2'(and 3')-Methylene-3'(and 2')-O-Thiocarbonyl Derivatives and Radical Reuction of a 2'-Chloro-3'Methylene Analogue," <i>Can. J. Chem.</i> , 71: 186-191 (1993).	
	C106	Samano, et al., "Synthesis and Radical-Induced Ring-Opening Reactions of 2'-Deoxyadenosine-2'-Spirocyclopropane and its Uridine analogue. Mechanistic Probe for Ribonucleotide Reductases," <i>J Am Chem Soc</i> , 114: 4007-08 (1992).	
	C107	Sandhu, et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." <i>Drug Metabolism and Disposition</i> (2004), 32(11), 1254-1259	
	C108	Sato, et al., "C-Nucleoside synthesis. 10. Synthesis of 2'-methylated pyrimidine C-nucleosides." <i>Tetrahedron Letters</i> (1980), 21(20), 1971-4.	
	C109	Sato, et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." <i>Bulletin of the Chemical Society of Japan</i> (1983), 56(9), 2680-99.	
	C110	Scheibler, C., "Ueber das Saccharin und die Saccharinsaure," <i>Chemische Berichte</i> , 13:2212-2217 (1880). In German. 1980	
	C111	Schiff, E.R., "Emerging strategies for pegylated interferon combination therapy," <i>Nature Clinical Practice Gastroenterology and Hepatology</i> , (2007) Vol. 4, No. SUPPL. 1, pp. S17-S21.	
	C112	Schmidt, C., et al., "The effects of 2'- and 3'-alkyl substituents on oligonucleotide hybridization and stability," <i>Bioorg. &amp; Med. Chem. Lett.</i> , 4(16): 1969-1974 (1994).	
	C113	Serafinowski, P.J., et al., "New method for the preparation of some 2'- and 3'-trifluoromethyl-2',3'-dideoxyuridine derivatives," <i>Tetrahedron</i> , 56(2):333-339 (1999).	
	C114	Shim, Jae H., "Recent patents on nucleoside and nucleotide inhibitors for HCV," <i>Recent Patents on Anti-Infective Drug Discovery</i> (2006), 1(3), 323-331.	
	C115	Smith, et al., "Synthesis of new 2'-β-C-methyl related triciribine analogues as anti-HCV agents." Valeant Pharmaceuticals International, Costa Mesa, CA, USA. <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2004), 14(13), 3517-3520.	
	C116	Song, et al., Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Medicated Transport," <i>Molecular Pharmaceutics</i> (2005), 2(2), 157-167.	
	C117	Sorbera, L.A., et al., "Valopicitabine: anti-hepatitis C virus drug RNA -directed RNA polymerase (NS5B) inhibitor," <i>Drugs of the Future</i> (2006), 31 (4), 320-324.	
	C118	Sowden, J., "The Saccharinic Acids," <i>Adv. Carbohydrate Chem.</i> , 12:43-46 (1957).	
	C119	Spardari, et al., "L-Thymidine is Phosphorylated by Herpes Simplex Virus Type I Thymidine Kinase and Inhibits Viral Growth," <i>Journal of Medicinal Chemistry</i> , 35(22), 4214-4220 (1992).	
	C120	Standring, D.N., et al., "Antiviral Beta-L-Nucleosides Specific for Hepatitis B Virus Infection," <i>Antiviral Chem. &amp; Chemother.</i> , 12 (Suppl. 1): 119-129 (2001).	
	C121	Stuyver, et al., "Ribonucleoside Analogue That Block Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture." <i>Antimicrobial Agents and Chemotherapy</i> , Vol 47, No. 1, Jan. 2003, p. 244-254.	
	C122	Sundberg, et al., Advanced Organic Chemistry, Part b, 1990, pages 232 and 236.	
▼	C123	Takenuki, et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2'-ketonucleosides." <i>Chemical &amp; Pharmaceutical Bulletin</i> (1990), 38(11), 2947-52.	
/TM/	C124	Tang, X.-Q., et al., "2'-C-Branched Ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-B-Methylcytidine and Their Incorporation into Oligonucleotides." <i>J. Org. Chem.</i> , 64(3): 747-754 (1999).	

LAI-2881655v1

EXAMINER	/Traviss McIntosh III/ (01/22/2008)	DATE CONSIDERED	01/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)


<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	11874-055-999
	10/608,907
<b>APPLICANT</b>	<b>CONFIRMATION NO.</b>
Storer, et al.	2201
<b>FILING DATE</b>	<b>ART UNIT</b>
June 27, 2003	1623

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/TM/	C125	Tritsch, D., et al., "3'- $\beta$ -ethynyl and 2'-deoxy-3'- $\beta$ -ethynyl adenosines: First 3'- $\beta$ -branched adenosine substrates of adenosine deaminase," <i>Bioorg. &amp; Med. Chem. Lett.</i> , 10: 139-141 (2000).	
/TM/	C126	Tunitskaya, V.L., et al., "Substrate properties of C'-methyl UTP derivatives in T7 RNA polymerase reactions. Evidence for N-type NTP conformation," <i>FEBS Letters</i> , 400: 263-266 (1997).	
	C127	Tyrsted, G., et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxyadenosine and structurally related nucleoside analogs," <i>Biochem. Biophys. Acta</i> , 155(2): 619-622 (February 26, 1968).	
	C128	Usui, H., et al., "Synthesis of 2'-deoxy-8,2'-ethanoadenosine and 3'-deoxy-8,3'-ethanoadenosine (Nucleotides & Nucleosides. LXIV)," <i>Chem. Pharm. Bull.</i> , 34(1):15-23 (1986).	
	C129	Vassilev, V., et al., "Bovine Viral Diarrhea Virus Induced Apoptosis Correlates with Increased Intracellular Viral RNA Accumulation." <i>Virus Research</i> , 69: 95-107 (2000).	
	C130	Verri, A., et al., "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of B-L-deoxycytidine analogs as antineoplastic and antiviral agents," <i>Molecular Pharmacology</i> , 51(1): 132-138 (January 1997).	
	C131	Verri, a., et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues," <i>Biochem. J.</i> , 328(1): 317-320 (November 15, 1997).	
	C132	Von Buren, et al., "Branched oligodeoxynucleotides: automated synthesis and triple helical hybridization studies." <i>Tetrahedron</i> (1995), 51(31), 8491-506.	
	C133	Von Janta-Lipinski, M., et al., "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified B-2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular SNA Polymerases a, B, y, d and E Nor HIV-1 Reverse Transcriptase," <i>J. Medicinal Chemistry</i> , 41(12): 2040-2046 (May 21, 1998).	
	C134	Wagner, D., et al., "Preparation and Synthetic Utility of Some Organotin Derivatives of Nucleosides," <i>J. Org. Chem.</i> , 39(1):24-30 (1974).	
	C135	Walczak, K., et al., "Synthesis of 1-(3-alkyl-2,3-dideoxy-D-pentofuranosyl)uracils with potential anti-HIV activity," <i>Acta Chemica Scand.</i> , 45: 930-934 (1991).	
	C136	Walton, et al., "Branched-Chain Sugar Nucleosides: V. Synthesis and Antiviral Properties of Several Branched-Chain Sugar Nucleosides," <i>Antiviral Nucleosides</i> , Vol. 12: 306-309 (1969).	
	C137	Whistler, R. L., and BeMiller, J.N., "[118] 'a'-D-Glucosaccharino-1,4-Lactone," <i>Methods in Carbohydrate Chemistry</i> , 2:484-485 (1963).	
	C138	Wohnsland, A., et al., "Viral determinants of resistance to treatment in patients with hepatitis C," <i>Clinical Microbiology reviews</i> , (2007) Vol. 20, No. 1, pp. 23-38.	
	C139	Wolfe, et al., <i>Tetrahedron Letters</i> , Vol. 36(42): 7611-14 (1995).	
	C140	Wu, et al., "A New Stereospecific Synthesis of [3.1.0] Cyclic Cyclopropano Analog of 2',3'-Dideoxyuridine." <i>Tetrahedron</i> , vol. 46, 1990, pages 2587-2592.	
	C141	Zemlicka, J., et al. "Aminoacyl Derivatives of Nucleosides, Nucleotides, and polynucleotides. VIII. The Preparation of 2'(3')-O-L-Phenylalanyluridine, -cytidine, - Adenosine, -inosine, -guanosine and 2'-Deoxy-3'-O-L-Phenylalanyladenosine," <i>Collection Czecoslov. Chem. Commun.</i> 1969, Vol. 43, No. 13.	
↓	C142	Zemlicka, J., et al., "Substrate Specificity of Ribosomal Peptidyltransferase. Peditidyltransferase. Effect of Modifications in the Heterocyclic, Carbohydrate and Amino Acid Moiety of 2'(3')-O-L-Phenyladenosine." <i>Biochemistry</i> . December 2, 1975, Vol. 14, No. 24.	
/TM/	C143	Zinichenko, et al., "Substrate Specificity of Uridine and Purine Nucleoside Phosphorylases of the Whole Cells of <i>Escherichia Coli</i> ." <i>Nucleic Acids Research, Symposium Series No. 18.</i> , 1987, pp. 137-140.	

LAI-2881655v1

<b>EXAMINER</b>	/Traviss McIntosh III/ (01/22/2008)	<b>DATE CONSIDERED</b>	01/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11874-055-999	10/608,907
APPLICANT	CONFIRMATION NO.
Storer, et al.	2201
FILING DATE	ART UNIT
June 27, 2003	1623

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/TM/	A01	4,880,784	11/14/89	Robins, et al.	
	A02	5,156,797	10/26/93	Chou, et al.	
	A03	5,371,210	12/06/94	Chou, et al.	
	A04	5,401,861	3/28/95	Chou, et al.	
	A05	5,606,048	2/25/97	Chou, et al.	
	A06	5,821,357	10/13/98	Chou, et al.	
	A07	6,815,542	11/9/04	Hong, et al.	
	A08	6,914,054	7/05/05	Sommadossi, et al.	
	A09	7,101,861	9/05/06	Sommadossi, et al.	
	A10	7,105,493	9/12/06	Sommadossi, et al.	
	A11	7,148,206	12/12/06	Sommadossi, et al.	
	A12	7,157,441	1/02/07	Sommadossi, et al.	
	A13	7,163,929	1/16/07	Sommadossi, et al.	
	A14	2003/0055013	3/20/03	Brass	
	A15	2004/0077587	4/22/04	Sommadossi, et al.	
	A16	2004/0097461	5/20/04	Sommadossi, et al.	
↓	A17	2004/0101535	5/27/04	Sommadossi, et al.	
/TM/	A18	2005/0124532	6/09/05	Sommadossi, et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
/TM/	B01	GB 1187824	5/02/66	Merck & Co., Inc.		
/TM/	B02	JP 06211890	8/02/94	Yamasa Shoyu Co. Ltd.	English abstract provided.	
/TM/	B03	WO 99/052514	10/21/99	Eli Lilly and Co.		
/TM/	B04	WO 04/065398	8/5/04	Ribapharm, Inc.		
/TM/	B05	WO 04/080466	9/23/04	Ribapharm, Inc.		
/TM/	B06	WO 05/012327	2/10/05	University College Cardiff Consultants Limited		

LAI-2888331v1

EXAMINER /Traviss McIntosh III/ (01/22/2008)

DATE CONSIDERED

01/22/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11874-055-999	10/608,907
	APPLICANT	CONFIRMATION NO.
	Storer, et al.	2201
FILING DATE		ART UNIT
June 27, 2003		1623

### FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
/TM/	B07	WO 05/021568	3/10/05	Biota, Inc.		
/TM/	B08	WO 05/030258	4/07/05	Dihedron Corp.		
/TM/	B09	WO 05/123087	12/29/05	Merck & Co., Inc.		
/TM/	B10	WO 06/002231	1/05/06	Biocryst Pharmaceuticals, Inc.		
/TM/	B11	WO 06/012078	2/02/06	Merck & Co., Inc.		

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/TM/	C01	Berenguer, M., et al., "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," Proceedings of the Association of American Physicians, 110(2), 98-112 (1998).	
/TM/	C02	Kotra, L., et al., "Structure-Activity Relationships of 2'-Deoxy-2',2'-difluoro-L-erythro-pentofuranosyl Nucleosides." J. Med. Chem. 1997, 40, 3635-3644.	
/TM/	C03	Kuhn, R., et al., "Uber eine molekulare Umlagerung von N-Glucosiden." Jahrg. 69, 1936, p. 1745-1754.	
/TM/	C04	Savochkina, et al., "Substrate Properties of C-MethylNucleoside Triphosphates in RNA Syntheses Catalyzed by E. Coli RNA - Polymerase." Molecular Biology, 1989, v. 23, no. 6.	
/TM/	C05	Zinchenko, et al., "2', 3' & .5' - uridine methyl derivatives in microbiological transelicozilation." Doklady Akad Nauk v.297(3), pp. 731-734.	
	C06	Zinchenko, et al., "Substrate specificity of uridine and purine nucleoside phosphorases in whole cells of e. coli" Biopolymers & a cell, 1988, v. 4, No. 6.	
no date			

LAI-2888331v1

EXAMINER /Traviss McIntosh III/ (01/22/2008)	DATE CONSIDERED 01/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	